"GB - Spojen\u00E9 kr\u00E1lovstv\u00ED Velk\u00E9 Brit\u00E1nie a Severn\u00EDho Irska" . . . . "Pharmacogenomics" . "5" . "For decades it has been well known that elevated levels of homocysteine are harmful to humans on the basis of clinical observations derived from classical model diseases, such as inherited metabolic disorders. This group of diseases includes classical homocystinuria and several other inherited diseases affecting the so-called 'transsulfuration pathways'. Homocysteine lies in a metabolic checkpoint that interconnects one-carbon-transferring reactions with metabolism of sulfur-containing amino acids, since every molecule of 5-methyltetrahydrofolate derived either from plasma or generated from other folate species must be demethylated to liberate the reduced tetrahydrofolate. This unidirectional mechanism operates in every cell and has no alternative in eukaryotic cells. Antifolates are a group of anticancer agents targeting various metabolic steps within folate metabolism. They exert an indirect influence on the rate of appearance/disappearance of homocysteine from cellular and plasma compartments. Rece"@en . "RIV/00209805:_____/04:00013645" . "1462-2416" . . "12"^^ . . "P(NC7104)" . . . . "1151; 1162" . "Homocystein: vyu\u017Eit\u00ED jako farmakodynamick\u00FD biomarker antifol\u00E1tov\u00E9 chemoterapie"@cs . "4"^^ . "Poruchy metabolismu homocyteinu jsou v medic\u00EDn\u011B zn\u00E1my des\u00EDtky let, jako vrozen\u00E9 choroby. Tato skupina chorob zahrnuje klasickou cystinurii i dal\u0161\u00ED transsulfura\u010Dn\u00ED poruchy, kde se jedn\u00E1 v\u017Edy o demethylaci a uvoln\u011Bn\u00ED redukovan\u00E9ho tetrahydrofol\u00E1tu. Antifol\u00E1ty jsou cytostatika atakuj\u00EDc\u00ED r\u016Fzn\u00E9 kroky fol\u00E1tov\u00E9ho metabolismu a ovliv\u0148uj\u00ED metabolismus homocysteinu v bu\u0148ce i plasm\u011B. To se projev\u00ED tak\u00E9 u terapie methotrexatem a tato role je nyn\u00ED aktu\u00E1ln\u011B studov\u00E1na . V klinick\u00E9 praxi jsou studov\u00E1ny genetick\u00E9 poruchy metabolismu fol\u00E1t\u016F a homocysteinu z hlediska farmakologie i famakogenetiky. Pr\u00E1ce navrhuje mo\u017En\u00E9 cesty u\u017Eit\u00ED homocysteinu jako biomarkeru antifol\u00E1tov\u00E9 terapie."@cs . . . . "[36E12B7CF8C1]" . "Homocysteine: exploring its potential as a pharmacodynamic biomarker of antifolate chemotherapy"@en . . "2"^^ . "Homocysteine: exploring its potential as a pharmacodynamic biomarker of antifolate chemotherapy"@en . . "For decades it has been well known that elevated levels of homocysteine are harmful to humans on the basis of clinical observations derived from classical model diseases, such as inherited metabolic disorders. This group of diseases includes classical homocystinuria and several other inherited diseases affecting the so-called 'transsulfuration pathways'. Homocysteine lies in a metabolic checkpoint that interconnects one-carbon-transferring reactions with metabolism of sulfur-containing amino acids, since every molecule of 5-methyltetrahydrofolate derived either from plasma or generated from other folate species must be demethylated to liberate the reduced tetrahydrofolate. This unidirectional mechanism operates in every cell and has no alternative in eukaryotic cells. Antifolates are a group of anticancer agents targeting various metabolic steps within folate metabolism. They exert an indirect influence on the rate of appearance/disappearance of homocysteine from cellular and plasma compartments. Rece" . . "566621" . . . . "Homocysteine: exploring its potential as a pharmacodynamic biomarker of antifolate chemotherapy" . "8" . "Homocystein: vyu\u017Eit\u00ED jako farmakodynamick\u00FD biomarker antifol\u00E1tov\u00E9 chemoterapie"@cs . "Antimetabolites, antineoplastic;biological markers;folic acid antagonists;homocysteine;methotrexate"@en . . "Val\u00EDk, Dalibor" . "Homocysteine: exploring its potential as a pharmacodynamic biomarker of antifolate chemotherapy" . "RIV/00209805:_____/04:00013645!RIV/2005/MZ0/L26005/N" .